CEFPROZIL POWDER FOR ORAL SUSPENSION POWDER FOR SUSPENSION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

CEFPROZIL (CEFPROZIL MONOHYDRATE)

Доступна с:

RANBAXY PHARMACEUTICALS CANADA INC.

код АТС:

J01DC10

ИНН (Международная Имя):

CEFPROZIL

дозировка:

250MG

Фармацевтическая форма:

POWDER FOR SUSPENSION

состав:

CEFPROZIL (CEFPROZIL MONOHYDRATE) 250MG

Администрация маршрут:

ORAL

Штук в упаковке:

50/75/100ML

Тип рецепта:

Prescription

Терапевтические области:

SECOND GENERATION CEPHALOSPORINS

Обзор продуктов:

Active ingredient group (AIG) number: 0127613004; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2009-08-20

Характеристики продукта

PRODUCT MONOGRAPH
PR
CEFPROZIL POWDER FOR ORAL SUSPENSION
CEFPROZIL POWDER FOR ORAL SUSPENSION USP
(250 MG/5 ML OF CEFPROZIL AS CEFPROZIL MONOHYDRATE, WHEN
RECONSTITUTED)
USP
ANTIBIOTIC
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive,
Brampton, Ontario
L6T 1C1
Date of Revision:
October 9, 2019
Submission Control No.: 230902
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 4
SUMMARY PRODUCT INFORMATION
.................................................................................
4
INDICATIONS AND CLINICAL USE
.......................................................................................
4
CONTRAINDICATIONS
............................................................................................................
5
WARNINGS AND PRECAUTIONS
...........................................................................................
5
ADVERSE REACTIONS
.............................................................................................................
7
DRUG INTERACTIONS
.............................................................................................................
9
DOSAGE AND ADMINISTRATION
.........................................................................................
9
OVERDOSAGE
.........................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
11
STORAGE AND STABILITY
...................................................................................................
12
STORAGE OF RECONSTITUTED SUSPENSION
................................................................. 12
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................................... 13
PART II: SCIENTIFIC INFORMATION
.....................................................................................
14
PHARMACEUTICAL INFORMATION
...................